Wuhan Hiteck Biological Pharma Co.,Ltd (SHE:300683)
China · Delayed Price · Currency is CNY 24.02
-1.35 (-5.32%)
Jul 30, 2026, 3:04 PM CST
SHE:300683 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 3,321 | 3,630 | 3,121 | 4,727 | 4,322 | 7,273 | |
Market Cap Growth | -42.21% | 16.32% | -33.98% | 9.35% | -40.56% | 72.12% |
Enterprise Value | 2,961 | 2,955 | 2,310 | 3,665 | 3,553 | 6,267 |
Last Close Price | 25.37 | 27.73 | 23.70 | 35.90 | 35.19 | 59.21 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | - | - | - | - | 262.98 |
Forward PE | - | 21.83 | 21.83 | 21.83 | 21.83 | 21.83 |
PS Ratio | 6.11 | 6.70 | 4.81 | 7.85 | 6.28 | 11.83 |
PB Ratio | 1.55 | 1.67 | 1.29 | 1.89 | 1.85 | 3.10 |
P/TBV Ratio | 1.91 | 2.07 | 1.66 | 2.44 | 2.25 | 3.79 |
P/OCF Ratio | - | - | 137.55 | 889.42 | 81.51 | 601.62 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 5.44 | 5.46 | 3.56 | 6.09 | 5.16 | 10.20 |
EV/EBITDA Ratio | - | - | - | - | 203.04 | 279.54 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.03 | 0.02 | 0.02 | 0.03 | 0.04 | 0.04 |
Debt / EBITDA Ratio | - | - | - | - | 4.12 | 3.64 |
Net Debt / Equity Ratio | -0.17 | -0.36 | -0.34 | -0.41 | -0.41 | -0.47 |
Net Debt / EBITDA Ratio | 5.44 | 11.60 | 29.56 | 14.48 | -54.50 | -49.06 |
Net Debt / FCF Ratio | 4.70 | 6.20 | 40.67 | 6.33 | 7.89 | 4.68 |
Asset Turnover | 0.20 | 0.20 | 0.22 | 0.21 | 0.26 | 0.25 |
Inventory Turnover | 3.54 | 3.38 | 3.37 | 3.11 | 3.74 | 3.75 |
Quick Ratio | 2.58 | 3.63 | 3.23 | 3.88 | 4.46 | 5.85 |
Current Ratio | 4.17 | 3.98 | 3.60 | 4.30 | 5.07 | 6.35 |
Return on Equity (ROE) | -10.78% | -10.28% | -3.01% | -5.31% | -0.34% | 1.48% |
Return on Assets (ROA) | -3.77% | -3.65% | -2.46% | -3.07% | -0.78% | -0.34% |
Return on Invested Capital (ROIC) | -10.26% | -10.87% | -7.61% | -9.79% | -2.57% | -1.34% |
Return on Capital Employed (ROCE) | -7.20% | -7.10% | -4.50% | -5.30% | -1.40% | -0.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | -7.24% | -6.37% | -2.22% | -2.56% | -0.33% | 0.38% |
FCF Yield | -2.36% | -3.50% | -0.65% | -3.43% | -2.80% | -3.23% |
Dividend Yield | - | - | 0.55% | - | - | - |
Payout Ratio | - | - | - | - | - | 0.22% |
Buyback Yield / Dilution | -0.24% | 0.14% | -0.71% | -1.86% | -19.91% | -2.00% |
Total Shareholder Return | -0.24% | 0.14% | -0.17% | -1.86% | -19.91% | -2.00% |